Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash from Investing Activities: 2022-2025

Historic Cash from Investing Activities for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to -$48,000.

  • Taysha Gene Therapies' Cash from Investing Activities fell 37.14% to -$48,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$344,000, marking a year-over-year increase of 10.88%. This contributed to the annual value of -$363,000 for FY2024, which is 95.06% up from last year.
  • As of Q3 2025, Taysha Gene Therapies' Cash from Investing Activities stood at -$48,000, which was down 177.42% from $62,000 recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Cash from Investing Activities high stood at $62,000 for Q2 2025, and its period low was -$11.4 million during Q1 2022.
  • Over the past 3 years, Taysha Gene Therapies' median Cash from Investing Activities value was -$48,000 (recorded in 2025), while the average stood at -$733,818.
  • Over the last 5 years, Taysha Gene Therapies' Cash from Investing Activities had its largest YoY gain of 230.00% in 2024, and its largest YoY loss of 518.75% in 2024.
  • Over the past 4 years, Taysha Gene Therapies' Cash from Investing Activities (Quarterly) stood at -$2.4 million in 2022, then surged by 99.58% to -$10,000 in 2023, then soared by 230.00% to $13,000 in 2024, then tumbled by 37.14% to -$48,000 in 2025.
  • Its last three reported values are -$48,000 in Q3 2025, $62,000 for Q2 2025, and -$371,000 during Q1 2025.